Швейцария - итальянский - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 20 mg, lactosum 244.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 132, e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Швейцария - итальянский - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 25 mg, lactosum 200 mg, cellulosum microcristallinum, carmellosum natricum solo tenuti insieme corrisp. sodio 0,8 mg, magnesio stearas, kapselhülle: gelatina, e-171, drucktinte: lacca, propylenglycolum, e 172 (nero), kalii hydroxidum, per una piccola scatola. - onkologikum - synthetika

Швейцария - итальянский - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 2.5 mg, lactosum 20 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.2 mg, magnesii stearas, kapselhülle: gelatina, e 132, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Швейцария - итальянский - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 5 mg, lactosum 40 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.4 mg, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Швейцария - итальянский - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 7.5 mg, lactosum 60 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.4 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Швейцария - итальянский - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 10 mg, lactosum 80 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 132, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Швейцария - итальянский - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 15 mg, lactosum 120 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 132, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Швейцария - итальянский - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 20 mg, lactosum 160 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.2 mg, magnesii stearas, kapselhülle: gelatina, e 132, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Швейцария - итальянский - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 25 mg, lactosum 200 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.2 mg, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Европейский союз - итальянский - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mieloma multiplo - agenti antineoplastici - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.